A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMA
Principal Investigator
Carol Aghajanian, MD
Status
Terminated
Date Opened To Accrual
July 03 2000
Date Closed to Accrual
September 13 2004
Date of Study Termination
January 27 2018
Disease Site
Gynecologic [GY]
Uterine Corpus
Phase
III
Developmental Therapeutics
No
Primary Objective
To compare treatment outcomes (survival and progression-free survival) in patients with Stages III-IV endometrial carcinoma (< 2 cm residual disease) treated with tumor volume directed pelvic plus or minus para-aortic irradiation followed by cisplatin and doxorubicin or cisplatin, doxorubicin and paclitaxel chemotherapy.
Patient Population
Target Accrual
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.